Anti-VEGF drugs, including bevacizumab and lenvatinib (multi-targeted tyrosine kinase inhibitors of VEGF), inhibit tumor development by inhibiting tumor angiogenesis. The gene discussed is VEGFA; the disease is neoplasm.